title: Pterin abnormalities in dystonia: a metabolic marker with therapeutic implications.
authors: National Institutes of Health, Bethesda, Maryland 20205.
authors: P A
authors: PA
authors: LeWitt
authors: L P
authors: LP
authors: Miller
authors: R A
authors: RA
authors: Levine
authors: W
authors: W
authors: Lovenberg
authors: R P
authors: RP
authors: Newman
authors: A
authors: A
authors: Papavasiliou
authors: A
authors: A
authors: Rayes
authors: R
authors: R
authors: Eldridge
authors: R S
authors: RS
authors: Burns
mesh_terms: D000328:Adult; D001708:Biopterins / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D002490:Central Nervous System / Q000378:metabolism; D004421:Dystonia / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008875:Middle Aged; D019798:Neopterin; D011622:Pterins / Q000134:cerebrospinal fluid / Q000378:metabolism*
chemical_list: D011622:Pterins; D001708:Biopterins; D006897:Hydroxyindoleacetic Acid; D019798:Neopterin; C003402:sapropterin; D006719:Homovanillic Acid